Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review

Health and Quality of Life Outcomes

Andrew Lloyd¹  Jacie T. Cooper²  Andrew Briggs³  Juan Jose Garcia Sanchez⁴  Elisabeth Sörstadius⁵  Phil McFarlane⁶ 

[1] Acaster Lloyd Consulting Ltd., London, UK;Avalon Health Economics, Morristown, NJ, USA;Avalon Health Economics, Morristown, NJ, USA;Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK;Health Economics and Payer Evidence Lead, Global Market Access & Pricing, AstraZeneca, Academy House, 136 Hills Road, CB2 8PA, Cambridge, UK;Price and Market Access Director, Global Market Access & Pricing. AstraZeneca, Mölndal, Sweden;University of Toronto, Toronto, Canada;

关键词: EQ-5D;    SF-6D;    HUI;    Cost-utility;    Cost-effectiveness;    Dialysis;    Transplant;   

DOI  :  10.1186/s12955-020-01559-x

来源: Springer

【 摘 要 】

BackgroundA Task Force from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) provides recommendations on how to systematically identify and appraise health state utility (HSU) weights for cost-effectiveness analyses. We applied these recommendations to conduct a systematic review (SR) to identify HSU weights for different stages of chronic kidney disease (CKD), renal replacement therapy (RRT) and complications.MethodsMEDLINE® and Embase were searched for interventional and non-interventional studies reporting HSU weights for patients with CKD stages 1–5 or RRT. As per ISPOR Task Force Guidance, study quality criteria, applicability for Health Technology Assessment (HTA) and generalisability to a broad CKD population were used to grade studies as either 1 (recommended), 2 (to be considered if there are no data from grade 1 studies) or 3 (not recommended).ResultsA total of 17 grade 1 studies were included in this SR with 51 to 1767 participants, conducted in the UK, USA, Canada, China, Spain, and multiple-countries. Health related quality of life (HRQL) instruments used in the studies included were EQ-5D-3L (10 studies), SF-6D (4 studies), HUI2/HUI3 (1 study), and combinations (2 studies). Although absolute values for HSU weights varied among instruments, HSU weights decreased with CKD severity in a consistent manner across all instruments.ConclusionsThis SR identified HSU weights for a range of CKD states and showed that HRQL decreases with CKD progression. Data were available to inform cost-effectiveness analysis in CKD in a number of geographies using instruments acceptable by HTA agencies.

【 授权许可】

CC BY